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ABSTRACT
T
he concept of gene therapy has long appealed to
biomedical researchers and clinicians because it
promised to treat certain diseases at their origins. In
the last several years, there have been several trials in which
patients have beneﬁted from gene therapy protocols. This
progress, however, has revealed important problems,
including the problem of insertional oncogenesis. In this
review, which focuses on monogenic diseases, we discuss the
problem of insertional oncogenesis and identify areas for
future research, such as developing more quantitative assays
for risk and efﬁcacy, and ways of minimizing the genotoxic
effects of gene therapy protocols, which will be important if
gene therapy is to fulﬁll its conceptual promise.
Introduction
With the recognition that thousands of diseases are caused
by changes in single genes, so-called monogenic diseases, and
the advent of recombinant DNA technology, the idea that one
could manipulate the nucleic acid content of diseased cells to
cure disease, ‘‘gene therapy,’’ was born. In 1978, David
Baltimore summarized the promise of gene therapy and the
optimism that many felt:
. . . it would be a triumph of medicine if the effects of such
genes could be countered. . . . One approach involves altering
some cells of the body so that they can carry out the needed
function. A patient could, for instance, be treated in this way
for a blood disease caused by an abnormal protein made by a
mutant gene. A normal gene would be inserted into the
precursor cells—immature bone marrow cells that ultimately
develop into functioning blood cells. In this way, a normal
protein could be made in place of, or along with, the aberrant
protein. The genetically altered blood cell precursor could then
cure the patient’s disease. . . . It is likely to be the ﬁrst type of
genetic engineering tried on human beings, and might be tried
within the next ﬁve years. [1]
In the eyes of the public, general scientists, and practicing
physicians this potential remains unrealized. While progress
has not occurred as fast as anticipated, the strategy that Dr.
Baltimore outlines remains one of the working paradigms in
the ﬁeld and would still be a ‘‘triumph of medicine.’’ This
review brieﬂy examines recent progress in the ﬁeld and looks
forward to areas of study that we perceive as being essential
so that 28 years from now gene therapy is not seen as
something that once had great promise. We will discuss the
importance of developing more quantitative assays for both
efﬁcacy and risk, and ways to minimize the risk of gene
therapy protocols. A major focus of gene therapy research
has been, and will continue to be, the development of viral
vectors for gene delivery, including novel adenoviruses,
adeno-associated viruses, herpes simplex viruses, and
retrovirus (including foamy and lentiviruses). A thorough
discussion of these vector delivery systems is beyond the
scope of this review, and comprehensive discussions of the
different viral vectors used in gene therapy can be found
elsewhere [2–4].
Summary of Recent Clinical Trials of Gene Therapy
for Monogenic Diseases
In the last decade there have been four monogenic diseases
for which seminal gene therapy trials have been conducted:
ornithine transcarbamylase (OTC) deﬁciency, hemophilia
caused by factor IX deﬁciency, severe combined
immunodeﬁciency (SCID), and chronic granulomatous
disease (CGD), the results of which are brieﬂy summarized in
Table 1 [5–12]. Signiﬁcant attention has been paid to the
serious adverse events that have come from these trials, and
in fact we use these adverse events as a basis for formulating
future areas of research in gene therapy. It must be
highlighted, however, that an increasing number of patients,
particularly those with SCID, have beneﬁted from
participating in these gene therapy trials. Moreover, for most
of these diseases, contemporary therapy is either inadequate
or associated with serious adverse events themselves.
Evaluation of the gene therapy trials must be done in the
context of currently available treatments. Finally, as with any
new therapy, for example the development of bone marrow
transplantation and solid organ transplantation, there will be
growing pains. It would be naively unrealistic to expect that
gene therapy will not suffer similar pains. These growing
pains have taught us about new obstacles that need to be
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of viral vectors and the problem of insertional oncogenesis.
Problems with In Vivo Administration of Viral
Vectors
A ﬁrst problem is the immune response to in vivo–
administered viral vectors. Many viral proteins are capable of
eliciting an immune response, the magnitude of which may be
difﬁcult to predict and varies from patient to patient. In the
OTC trial, this variable inﬂammatory response resulted in the
death of one patient; and in the hemophilia trials, the
immune response eliminated virally transduced cells thereby
abrogating any potential beneﬁt. Transient or long-term
immunosuppression is a possible solution to this problem
which we will not discuss further here.
A second problem with in vivo administration of viral
vectors is that multiple cell types are exposed to the risks of
being infected with the administered virus. In the in vivo
administration of viral vectors, certain cell types are the
desired target because they have the greatest chance of giving
clinical beneﬁt. But multiple other cell types, which have a
low likelihood of contributing to clinical effectiveness, are
exposed to potential infection with the viral vector and the
possible deleterious consequences, such as activation of the
inﬂammatory response or insertional oncogenesis if an
integrating viral vector is used.
A third problem with the in vivo administration of viral
vectors is the risk of germ line transduction. While germ line
transduction has not been observed so far, if inadvertent
germ line transduction did occur, it could create a public
outcry against gene therapy in general.
Insertional Activation of Proto-Oncogenes
The SCID and CGD trials have been the ﬁrst ‘‘successful’’
gene therapy trials, as some patients have beneﬁted from the
procedure. Nonetheless, the French SCID trial and the CGD
trial have also shown that the insertional activation of proto-
oncogenes is a serious problem that can result in either
leukemia or a clonal myeloproliferative condition [9,12]. In
both of these trials, a murine leukemia derived replication-
incompetent retroviral vector was used to infect puriﬁed
CD34
þ cells with the transgene being driven by the retroviral
long terminal repeat (LTR). In the French SCID trial, three
patients developed leukemia between two and three years
after the infusion of transduced cells from the activation of
the LMO-2 proto-oncogene [9,13]. In the CGD trial, the
insertional activation of the MDS1-EVI1 genes (EVI1 is a
transcription factor involved in the development of some
myeloid leukemias [14]) may have contributed to clinical
beneﬁt but also led to a clonal myeloproliferation resembling
a pre-leukemic state [12]. Whether these patients will develop
leukemia or myelodysplasia remains to be seen. For both
trials, preclinical studies were neither robust nor quantitative
enough to detect the risk of the insertional oncogenesis.
Subsequent murine studies have revealed that the risk of
developing T cell leukemia from retroviral activation of the
LMO-2 proto-oncogene might have been anticipated [15–17].
One of the interesting observations from these human
trials is that the clonal disorders arose in the cell lineage for
which there is an underlying defect (T cells in the SCID trial,
myeloid cells in the CGD trial) and not in lineages that did
not have a disorder (for example, there has been no evidence
of myeloproliferation in the SCID trials). The underlying
reason for this phenomenon is not clear but may relate to an
interaction between the transgene expressed, the integration
site of the viral vector, and the proliferation of the particular
cell type. Understanding these relationships has important
ramiﬁcations for the future of gene therapy research and for
our understanding of the oncogenic process in general.
Oncologic Principles Relevant to Gene Therapy
The nature of the oncogenic process has been an area of
intense study longer than the existence of the ﬁeld of gene
therapy. It is now apparent that these two ﬁelds, in addition
to the evolving ﬁeld of stem cell biology, are intertwined.
Through the studies of numerous investigators, including
Bishop and Varmus who proved that cancer is a genetic
disease, Knudson who proposed the ‘‘two-hit’’ model of
oncogenesis, Ashley who mathematically deduced the multi-
hit nature of oncogenesis, Vogelstein and Kinzler who
proposed the multi-step model for cancer, and Weinberg and
Hahn who deﬁned critical molecular aspects of these hits,
cancer is now understood to require on the order of four to
six genetic lesions [18–22]. Studies of somatic genomic
mutation rates show that the acquisition of genetic lesions is a
continuous and cumulative process and that one in three
people will develop enough hits in a single cell by the age of
80 to develop cancer. People who inherit a single ‘‘hit’’ in a
tumor suppressor gene such as p53 (Li-Fraumeni syndrome)
have a lifetime risk of developing cancer of 100%. Cancers in
Li-Fraumeni patients can take months to years to decades to
develop. Furthermore, studies of pediatric acute
lymphoblastic leukemia show that the leukemic clone can be
present at birth and not manifest itself as a life-threatening
disease until years later [23,24]. Thus, observing a mouse for
several months is not sufﬁcient to assess the oncogenic risk
for a particular protocol. Any process that speeds the
creation of genetic hits, such as viral insertions, will hasten
the development of cancer.
Gene therapy strategies employing the use of many viral
vectors, such as retroviral vectors, are based on the
uncontrolled integration of a therapeutic gene. A
fundamental problem with this strategy is that hundreds of
millions of cells are infused, each of which has acquired at
least one genetic hit. Even those viruses that are ‘‘non-
integrating,’’ such as recombinant adeno-associated virus
(rAAV), have a low rate of random integration that in clinical
gene therapy trials could potentially cause billions of
insertional mutations [25]. These hits are likely to be more
problematic than random mutations, as viral vectors
preferentially integrate into the coding or regulatory regions
of expressed genes, often resulting in upregulation of the
genes into which they integrate [25–27]. Thus, it is almost
certain that multiple proto-oncogenes will be activated in any
retroviral or lentiviral gene therapy protocol. It is also likely
that insertional mutagenesis may inactivate one allele of a
number of tumor suppressors. Although this inactivation is
not likely to result in cancer in the short-term, it may lead to
an increased risk of cancer years to decades later—when
those cells will have had the time to acquire additional
mutations through the normal ravages of life. Finally, an
increased risk of cancer is associated with increased
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envision expansion and proliferation of transduced cells as
an important component to clinical efﬁcacy, this also
increases the risk of subsequent oncogenesis.
This somewhat pessimistic assessment highlights that
signiﬁcant challenges remain for gene therapy. Conquering
these challenges will require more quantitative ways to assess
both risk and efﬁcacy and novel approaches to improve the
risk–beneﬁt ratio. We expect that as any new advance is made
that might improve the risk–beneﬁt ratio, including those
discussed below, the improvement must be assessed
quantitatively.
Developing Quantitative Models of Cancer Risk
Assessment for Gene Therapy Protocols
The preclinical assessments of the safety of gene therapy
protocols have been inadequate in giving a preclinical
assessment of the risk of oncogenesis in human studies. These
preclinical safety models have been inadequate for three
reasons: 1) analysis of an insufﬁcient number of integration
events, 2) observation for an insufﬁcient length of time, and
3) subjective rather than quantitative assessment of risk.
Most preclinical studies of gene therapy are performed in
adult mice, the average weight of which is 20 g. Thus, giving a
mouse 100,000 transduced cells (5 3 10
6 cells/kg) with an
average of one integration event per cell (as was done by May
et al. [28]) is exposing the mouse to the potential
consequences of 100,000 insertional events. If a 70-kg person
were to receive 5 3 10
6 transduced cells/kg, they would be
exposed to the consequences of 350,000,000 insertional
events. If we assume that each insertional event has an equal
probability of causing cancer, then it would require studying
3,500 mice to assess the cancer risk for a single patient. If we
wanted to assess the cancer risk per 100 patients, we would
have to assess the cancer risk of 350,000 mice.
Even if the appropriate number of insertion events had
been studied in mice, wild-type mice remain an inadequate
model for the assessment of oncogenic potential because of
their short lifespan. Mice live, on average, two years. As
discussed above, the leukemias that developed in the French
SCID trial took more than two years to develop, and the
studies of the ontogeny of pediatric acute lymphoblastic
leukemia also show that it can take much longer than two
years for a leukemia to become apparent [9,23,24]. Thus, the
standard mouse model is inadequate for the quantitative
assessment of oncogenic risk.
Since all medical interventions carry some risk, it is
incumbent on gene therapy researchers to establish
quantitative measures of this risk. For example, it may be
found for a certain disease that one million cells with an
average of 1.3 integration events per cell per kilogram are
needed for efﬁcacy (or a total number 100 million (10
8)
insertion events). If the risk of oncogenic transformation per
integration event is 10
 10, then the risk of creating cancer is 1
in 100 and the risk–beneﬁt ratio supports using gene therapy.
If, on the other hand, the risk of oncogenic transformation
per integration event is 10
 9, then the risk of creating cancer
is 1 in 10 and the risk–beneﬁt ratio may not favor using gene
therapy. Of course, such decisions depend on the prognosis
for the disease, the risk–beneﬁt ratios for alternative
treatments, and we use these reasonable numbers for
illustrative purposes.
Proposed Quantitative Models for Assessment
of Risk
There are many possible methods to quantitate the risk of a
gene therapy protocol. These assays will evolve as our
understanding of oncogenesis improves and other possible
adverse events of gene therapy are revealed. We believe these
quantitative risk assessments should be performed not just
with current viral-based strategies but also with ones in the
future that may include the use of potentially improved viral
vectors, insulators, the use of targeted integration such as by
phiC31 integrase or zinc ﬁnger nucleases (ZFNs), and
manipulated stem cells.
We envision two general types of assays to assess the
oncogenic risk of a gene therapy protocol: cell-based and
mouse-based. Cell-based assays, such as the 3T3
transformation assay, are well-established and standardized.
3T3 cells are murine ﬁbroblasts that have escaped senescence
and passed through crisis but still retain characteristics of
nontransformed cells, such as contact inhibition and the
inability to grow as colonies in soft agar. A standard
procedure to assess the oncogenic property of a gene, a gene
variant, or a chemical compound is to determine the rate that
it transforms 3T3 cells into cells that can grow in soft agar. A
gene therapy protocol could be tested for its ability to
transform 3T3 cells. Ideally, the protocol would not
transform 3T3 cells above the background rate. Once that is
achieved, the gene therapy protocol could be more rigorously
evaluated by determining the rate it transforms 3T3 cells that
have been further sensitized to transformation, such as by co-
treatment with mutagenic chemicals or co-transformation
with a weak oncogene. By using sensitized 3T3 cells, subtle
differences between gene therapy protocols may be revealed.
The second way gene therapy protocols should be tested is
using quantitative animal models. Ideally, one would like an
animal model that in one to two years could accurately
predict the oncogenic risk in a human for 50 years. As
discussed above, standard mouse models are inadequate for
this purpose, and such an ideal model does not currently
exist. An alternative is to use mouse models that have been
sensitized to tumor development (cancer susceptibility
model). For example, if one were interested in studying the
oncogenic risk of a hematopoietic-based gene therapy
protocol, murine hematopoietic cells deﬁcient in p53 could
be tested. When p53
 /  hematopoietic cells are transferred to
isogenic p53 wild-type mice, the mice develop lymphoma
with a latency of about 2 mo [29]. Ideally, one would ﬁnd that
even if 100 million integration events (a hypothetical number
of events determined to be needed for clinical efﬁcacy for
that disease) were transferred into p53 deﬁcient cells, the
latency to lymphoma development would not change. The
protocol could be more rigorously tested by examining the
latency to lymphoma after further sensitizing the cells by
treatment with a chemical mutagen or co-transforming with a
weak oncogene. If in these models tumors were induced at a
rate 100-fold lower than that needed for clinical efﬁcacy it
would provide strong preclinical evidence that the protocol
was safe for human trials. Such a model is being used to
compare the rates of transformation by MLV- and HIV-based
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 / hematopoietic stem cells [13]. We have
outlined one such strategy to test the safety of a gene therapy
protocol in animals, but there are many different models one
could use, and these different models may be more
appropriate for different gene therapy protocols.
Establishing a uniform animal model for testing would be
beneﬁcial because it would allow different gene therapy
protocols to be directly compared. Moreover, it would be
useful to test the gene therapy protocols that have already
been used in human trials to correlate the rate of
transformation in an animal model to what was found in the
human trials, thereby establishing a baseline for future
studies.
In summary, quantitative assays for safety should be
developed. We have proposed potential cell-based and
mouse-based assays, but it is likely that researchers can
develop better quantitative cell- and animal-based models
that more accurately assess the oncogenic risk speciﬁc to each
gene therapy protocol. We acknowledge that the studies
outlined above set a high bar for gene therapy research. By
setting such a bar, however, we will retain the trust of the
patients, the public, and the funding agencies on which our
work depends.
Quantitative Measures of Efficacy
If the measure of risk is deﬁned on a per event basis, then
to rationally balance risk–beneﬁt, quantitative measures of
efﬁcacy per event must also be developed. To illustrate this
principle, we will use hemophilia B (factor IX deﬁciency) as
an example. To convert severe hemophilia to mild
hemophilia requires generating a circulating level of factor
IX of 5% (or 250 ngs/ml or approximately 500,000 nanograms
per total circulating volume for an average adult). If a
particular vector could, on average, generate 10 picograms
per event, then to achieve clinical efﬁcacy one would expect
50 million events to be necessary. If, on the other hand,
another vector gave 10 times as much factor per average
event, then 10-fold fewer events would be necessary and this
improvement in efﬁcacy might also translate into improved
safety. May et al. (2000), for example, used such a comparison
to demonstrate that a b-globin–expressing lentivirus with
longer hypersensitivity regions from the b-globin locus
control region was better than a vector with shorter
hypersensitivity regions [28]. It is likely that for each disease,
different quantitative measures will have to be established,
but once these measures are established, they will allow
rational comparison of different vector systems and
protocols.
Approaches to Minimizing the Oncogenic Risk of
Gene Therapy
To improve the risk–beneﬁt ratio of gene therapy, it is
important to continue to develop ways to minimize the risk of
insertional oncogenesis. Four possible ways to minimize the
risk are: 1) continued improvements in vector design, 2)
buffer the genome from the effect of viral integrations, 3)
develop ways to control transgene integration, or 4) develop
ways to expand a small number of genetically characterized
modiﬁed stem cells in vitro and then re-infuse these non-
oncogenic cells into the patient.
Improving Safety through Modified Vectors
In the two gene therapy trials that caused proliferative
diseases, the investigators used a retroviral vector using the
viral LTR to drive expression of the transgene. In the last
several years, different vectors have been formulated, such as
self-inactivating vectors and lentiviral vectors, which may
have improved safety. In addition, improvements in safety
may be gained by using tissue-speciﬁc promoters to drive
transgene expression. These tissue-speciﬁc promoters may
give increased transgene expression thereby increasing the
efﬁcacy per given event, and thus fewer events would be
needed for clinical efﬁcacy. By using more speciﬁc promoters,
more tightly regulated expression may be obtained that might
also minimize the potential oncogenic properties that
overexpression may entail. In retroviral and lentiviral vectors,
however, the LTR would still be present and could still
potentially act as an enhancer for neighboring genes. It is also
possible that more speciﬁc promoters will not confer
signiﬁcant safety advantages. In the SCID and CGD trials, for
example, insertional activation of a proto-oncogene occurred
in a cell-type–speciﬁc manner and not in a heterologous cell
type.
An alternative vector system is to use transposons as a
nonviral delivery method. Transposon-based delivery systems
have been shown to work in a wide variety of cell types,
including stem cells [30]. In their current formulations,
however, the integration events remain uncontrolled and
thus may suffer the same problems of integration-based viral
delivery systems. In fact, transposon-based insertions are
being developed as a tool for cancer gene discovery [31]. An
active but still preliminary area of research is to try to create
hybrid transposases to target transposon integration to
deﬁned regions of the genome.
Buffering the Genome Using Insulators
Viral integrants under the control of LTR promoters can
activate genes near the insertion site [9,12,32]. Buffering the
genome surrounding the insertion site might be beneﬁcial in
minimizing such effects. Insulators are small DNA elements
that act as barriers thereby preventing promoter–enhancer
elements and/or chromatin modiﬁcations from inﬂuencing
the expression of neighboring genes [33]. The cHS4 insulator,
derived from the chicken b-globin locus, is the insulator
being studied most intensely for gene therapy purposes.
When insulators are incorporated into integrating retroviral
vectors being developed for gene therapy purposes, position-
effect variegation is decreased and the amount of transgene
expressed is increased for each insertion [34–36]. It is hoped
that insulators will protect the surrounding genome from
insertional activation from retroviral LTRs. From the
structural organization of such vectors, however, one would
only expect a decrease but not an elimination of LTRs acting
as enhancers on neighboring genes. Studies directly testing
the degree to which insulators protect the surrounding
genome from LTRs are ongoing, the publication of which is
much anticipated. While insulators may protect the genome
from the insertional activation of proto-oncogenes, they may
be limited because they will not protect against the
insertional inactivation of tumor suppressors by viral
integrations.
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Insertion
An alternative to buffering the genome from an
uncontrolled integration site is to target integration to ‘‘safe’’
genomic locations. Currently there are two possible methods
being developed to target transgene integrations: the use of
the phage C31 integrase and homologous recombination.
Targeting integration with /C31 integrase. Michelle Calos
and colleagues have developed vectors based on the /C31
integrase [37]. The Streptomyces phage integrase C31 catalyzes
efﬁcient site-speciﬁc recombination between two relatively
short (;30–40 bp) sequences. In the natural phage life cycle,
the temperate phage infects bacteria and integrates into the
host genome. To accomplish integration, the phage encodes
/C31 integrase, which catalyzes recombination between the
phage DNA through the phage attachment site, attP, and the
bacterial DNA through the bacterial attachment site, attB. In
mammalian cells, /C31 has been used to mediate integration
of plasmids encoding the attB site into a limited number of
native sequences bearing partial sequence homology with the
attP sites called pseudo attP sites.
Recent studies using vectors based on the /C31 integrase
have been able to demonstrate stable genomic integration,
prolonged expression of therapeutic genes, and have shown
efﬁcacy in models of tyrosinemia type I [38], epidermolysis
bullosa [39], factor IX deﬁciency [40], and SCID-X1 [41].
While targeting transgene integration with /C31 is showing
promise, there are several remaining issues. One issue is
whether the expression of the integrase causes genomic
instability. Studies examining the integration speciﬁcity of
the phage /C31 integrase into the human genome have
estimated that there are between 100 and 1,000 pseudo-attP
sites. There is concern and some evidence that the /C31
integrase may catalyze recombination between these pseudo-
attP sites, thereby causing genomic instability [42]. To
minimize these genotoxic effects, directed evolution is being
used to modify the /C31 integrase to improve the speciﬁcity
of its action to a more limited number of sites [43].
Using homologous recombination to minimize genotoxic
effects. A conceptually appealing way to treat monogenic
diseases caused by small mutations is to use homologous
recombination to correct the mutations while leaving the rest
of the genome untouched. In diseases caused by larger
mutations, such as the chromosomal inversion that causes
almost 50% of the cases of severe Factor VIII deﬁciency, one
could use homologous recombination to target the transgene
to a deﬁned genomic location. In mammalian cells, however,
the spontaneous rate of homologous recombination is on the
order of 10
 6 and thus too low to be considered for gene
therapy purposes [44,45]. Recently, two strategies have been
found that increase the rate of homologous recombination to
levels that might be of therapeutic use: the use of rAAV and
the use of DNA double-strand breaks (DSB).
In 1998, Russell and Hirata reported that cells infected with
rAAV underwent a high rate of homologous recombination
[46]. Russell’s group subsequently demonstrated that rAAV
could correct a variety of lesions in a wide range of cell types
[47]. The mechanism by which rAAV mediates high rates of
gene targeting remains unclear but does seem to involve the
cell’s endogenous homologous recombination machinery.
Building on this work, the Russell group then used rAAV-
mediated homologous recombination in mesenchymal stem
cells to inactivate a dominant mutation in the collagen
Col1A1 gene that causes osteogenesis imperfecta [48]. By
inactivating the dominant mutation, they demonstrated that
the cells had phenotypic correction of the underlying defect.
Several issues remain with rAAV-mediated homologous
recombination. To obtain recombination rates of useful
magnitude, infection of cells with high multiplicity of
infections is required, increasing the incidence of random
integration. In fact, most integration events will be
nonhomologous rather than homologous. A study of these
nonhomologous rAAV integration events showed that many
were associated with chromosomal rearrangements and
occurred in the control regions of genes [25,49].
A second method of stimulating homologous
recombination is by inducing DNA DSBs in the target locus.
In the mid-1990s a number of labs demonstrated that a
speciﬁc DSB in a genomic target created by the I-SceI homing
endonuclease stimulated homologous recombination
between the genomic target and transfected plasmid (‘‘gene
targeting’’) by 1,000-fold [50]. With optimization, gene
targeting rates of 3%–5% can be obtained [44]. The
limitation of this approach is that endogenous genes do not
contain recognition sites for I-SceI or other homing
endonucleases. If DSBs are to be used to stimulate gene
targeting, a method to create site-speciﬁc DSBs needed to be
developed. ZFNs have shown promise in being such a reagent.
These nucleases are artiﬁcial proteins in which a zinc ﬁnger
DNA binding domain is fused to the nuclease domain derived
from the type IIS restriction enzyme FokI and were ﬁrst
developed by Chandrasegaran and his colleagues [51,52]. The
ﬁrst demonstration that ZFNs might be useful for gene
therapy was in 2003 when Porteus and Baltimore
demonstrated that model ZFNs could stimulate gene
targeting by several-thousand–fold [44]. Urnov et al. (2005)
then showed that ZFNs could be designed to recognize an
endogenous target gene, in this case the IL2RG gene, and to
create targeting rates of 20% in the human K562 cell line and
5% in primary human T cells [53]. These results provide
optimism about the possibility of using ZFNs to stimulate
homologous recombination for therapeutic purposes.
One of the appeals of ZFNs is that they can be modiﬁed to
recognize novel target sequences. Theoretically it may be
possible to make ZFNs to essentially any target sequence, but
a current area of active research is to establish the best
practical method to do this. Barbas and his colleagues have
released a program that allows users to examine a sequence of
interest for binding sites to which zinc ﬁngers can be
assembled (http://www.zincﬁngertools.org). Whether this
relatively simple modular-assembly approach is good enough
to make highly active and speciﬁc ZFNs or whether more
complex selection-based approaches are needed remains to
be determined.
In the continued development of ZFNs, it is important to
demonstrate that ZFNs do not create oncogenic mutations.
DSBsareknowntobemutagenicandcanleadtochromosomal
translocations. Studies of ZFNs in model organisms and
mammalian cells have demonstrated that they cause
cytotoxicity by the creation of DSBs [44,54]. It is critical,
therefore,todesignZFNsystemsthatminimizetheseoff-target
DSBs and to show that these systems do not cause oncogenic
mutations/translocations using the cell-based and mouse-
PLoS Genetics | www.plosgenetics.org September 2006 | Volume 2 | Issue 9 | e133 1290model systems described earlier. An additional potential
problem is that the donor DNA can also integrate in a random
fashion. While the donor can be engineered so it is promoter-
less and enhancer-less to minimize insertional activation of
nearby genes, the random integration of the donor could still
potentially inactivate genes (such as tumor suppressors).
We have discussed using rAAV and DSBs as independent
ways to stimulate homologous recombination. Two papers
have shown that rAAV and DSBs generated using the I-SceI
endonuclease can act together to stimulate homologous
recombination [55,56]. Studies to determine if rAAV and
ZFNs act in a similar manner are ongoing.
Using Stem Cell Expansion to Make Gene
Therapy Safer
An approach to make gene therapy safer is to take
advantage of the ability of stem cells to expand. In this
scenario, gene transfer would occur in vitro. Individual or
small pools of cells would be isolated, expanded, and
characterized. Those clones or pools of cells that were
determined to have safe and effective integrations would be
further expanded, generating enough cells to reinfuse into the
patient. For hematopoietic diseases, the major limitation to
this approach is the inability to sufﬁciently expand individual
hematopoietic stem cells in vitro. Theoretically, one might
generate corrected cells by ﬁrst using gene targeting in
patient-speciﬁc human embryonic stem (ES) cells, then
expanding the targeted clones in vitro to generate sufﬁcient
numbers, followed by differentiation of clones into the tissue-
speciﬁc stem cells of choice. A proof of principle of this type
of gene therapy has been performed in a mouse model of
SCID, but several major problems remain [57]. One of the
problems for hematopoietic diseases is being able to convert
ES cells into hematopoietic stem cells that can give rise to
deﬁnitive hematopoiesis without having to use transgenes that
are associated with leukemias. The general problem of
turning human ES cells into tissue-speciﬁc stem cells that can
then integrate themselves into the host remains great, but the
potential utility is enormous, and this remains an exciting
area of research that is directly relevant to gene therapy.
Summary
The seeming conceptual simplicity of gene therapy has
belied the difﬁculty in its actual implementation. Despite
waning enthusiasm from the general scientist, gene therapy
researchers have persisted in tackling each problem as it has
presented. In this review, we have highlighted the next set of
problems and some possible solutions for the gene therapy
ﬁeld. We have consciously proposed criteria that set a high
bar. We believe, however, that the tortoise had it right: slow
and careful is fast, and ultimately we are optimistic that gene
therapy will fulﬁll its promise. “
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